Next Pharma Inc.

Next Pharma Inc. offers patients with non-invasive, highly accurate, reliable, fast and cost-effective AABH detection test kits, which can be used for early diagnosis, remission and recurrence of cancer following the treatment. Early diagnosis and treatment of cancer can play a key role in increasing patient’s chances of survival. However, current cancer diagnostic modalities are still not accurate enough, may take up to several months to obtain results and the associated costs are extremely high. Next Pharma Inc. has collaborated or is still collaborating with various Pharmaceutical firms, Medical Universities and Hospitals in China, USA, India, Iraq, Canada, Kuwait, Saudi Arabia, Australia and Poland, where teams of researchers are continuing advances on the Company’s core technologies. The Company is focused on areas of unmet clinical and medical need in which any significant progress could be a breakthrough; can have a high impact in healthcare policies / procedures and any developed product would have the potential of being a commercial blockbuster.

Next Pharma Inc. is establishing Clinical Diagnostic Laboratories initially in Toronto and very soon in other countries including USA, Saudi Arabia, UAE, Qatar, China, India,Iraq, Hong Kong, Taiwan, Kuwait, Poland, Italia, Germany, France, Turkey, Azerbaijan, Ireland to perform diagnostic test for cancer as a Laboratory Developed Test (LDT).  New tests to detect additional cancers will be added to the menu of tests offered by Next Pharma as they are developed. Next Pharma Inc. will provide all the necessary reagents, as well as training and technical support to all international partners to establish their local State-of-The-Art Laboratory. Next Pharma is headquartered in Toronto, Ontario, Canada.
Market:

Cancer as a disease is one of the world’s worst public health and financial problems. Statistics from the Canadian Cancer Society for 2017 indicate that an estimated around 360,900 people were diagnosed with cancer in Canada and 74,600 people are estimated to have died of cancer in 2017 (about 205 people a day). The Canadian Cancer Society estimate overall costs for cancer in on year at about $14.2 billion: $2.5 billion for direct medical costs; $11.8 billion indirect costs related to lost productivity and morbidity and mortality. Overall cancer market in each year is about $895 Billion (USA Today).

Synonyms: AABH, ASPH, A beta H-J-J, AAH, ASP beta-hydroxylase, BAH, Aspartate beta-hydroxylase, CASQ2BP1, Cardiac junctin, HAAH, Humbug, JCTN, Junctate, Junctin.